Chinese copper producer Xinxu Copper Industry (XXC.US) has increased its IPO size by 144% to raise $17 million.
Chinese copper producer Xinxu Copper Industry plans to more than double the size of its planned IPO in the United States.
Chinese copper and copper alloy products manufacturer XinXu Copper Industry (XXC.US) increased the planned size of its upcoming IPO on Monday. The company, headquartered in Wuhu, China, is now planning to issue 3 million shares of stock with an offering price range of $5 to $6 per share, raising $17 million. The company had previously filed for an IPO to issue 1.5 million shares of stock with an offering price range of $4 to $5 per share. Based on the revised offering price range, XinXu Copper Industry Technology's fundraising will increase by 144% compared to previous expectations, with an estimated market value of $127 million.
Through its operating subsidiary Anhui XinXu, the company is mainly engaged in the research and development, manufacturing and processing, sales, and distribution of copper and copper alloy products. Products include T2 red copper rods, T2 tin-plated copper rods, T2 copper rods, electrolytic copper, aluminum bars, etc.
The company's revenue for the twelve months ended December 31, 2024, was $123 million. The company plans to list on the NASDAQ with the stock code XXC. Craft Capital Management and R.F. Lafferty & Co. are the joint bookrunners for this transaction.
Related Articles
.png)
TRULY INT'L (00732) spent HKD 168,900 on January 27 to repurchase 164,000 shares.

Emperor Watch & Jewellery Limited (00887) announces that it expects the net profit for 2025 to be no less than 420 million Hong Kong dollars, representing a year-on-year increase of over 60%.

HENLIUS (02696): Clinical trial application for injection HLX43 combined with HLX07 and Hanshuang for the treatment of advanced solid tumors approved by the National Medical Products Administration.
TRULY INT'L (00732) spent HKD 168,900 on January 27 to repurchase 164,000 shares.
.png)
Emperor Watch & Jewellery Limited (00887) announces that it expects the net profit for 2025 to be no less than 420 million Hong Kong dollars, representing a year-on-year increase of over 60%.

HENLIUS (02696): Clinical trial application for injection HLX43 combined with HLX07 and Hanshuang for the treatment of advanced solid tumors approved by the National Medical Products Administration.

RECOMMEND

New Record Achieved As Spot Gold Tops $5,000 For The First Time; Institutions Set $6,600 Target
27/01/2026

117 Companies Raised Over HKD 285.6 Billion Through IPOs As Hong Kong Reclaims Global Leadership In 2025
27/01/2026

“A+H Hong Kong Listing Requires RMB 30 Billion Market Cap”? On‑Site Inquiry Dispels The Rumor
27/01/2026


